Figure 4.

Potential of intracellular antibodies in pancreatic cancer. (A) Intracellular antibodies can be used to block protein–protein interactions between KRAS and its effectors, RAF or PI3K, to directly degrade KRAS by targeted protein degradation or to block downstream signalling kinases, such as ERK and AKT, to inhibit cell proliferation, survival or invasion. (B) Intracellular antibodies could be employed to restore the function of tumour suppressors, such as P53, by modifying their conformation.